Analysts Anticipate Intellia Therapeutics Inc (NASDAQ:NTLA) Will Announce Earnings of -$0.61 Per Share
Equities research analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings of ($0.61) per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Intellia Therapeutics’ earnings, with estimates ranging from ($0.70) to ($0.56). Intellia Therapeutics posted earnings of ($0.53) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.1%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 30th.
On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.29) per share for the current fiscal year, with EPS estimates ranging from ($2.48) to ($2.13). For the next financial year, analysts anticipate that the company will post earnings of ($2.69) per share, with EPS estimates ranging from ($3.49) to ($1.97). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.05. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. The company had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $7.15 million. During the same quarter in the prior year, the company posted ($0.52) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 44.2% compared to the same quarter last year.
Shares of NASDAQ NTLA traded up $0.12 during midday trading on Thursday, reaching $17.48. The company had a trading volume of 249,449 shares, compared to its average volume of 580,991. The company’s 50-day moving average is $16.94. The company has a market cap of $852.85 million, a PE ratio of -8.83 and a beta of 2.62. Intellia Therapeutics has a 1 year low of $11.03 and a 1 year high of $32.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.99 and a current ratio of 7.99.
Several large investors have recently added to or reduced their stakes in NTLA. Benjamin Edwards Inc. increased its stake in shares of Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after acquiring an additional 640 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after acquiring an additional 1,000 shares during the period. Quantamental Technologies LLC increased its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock worth $56,000 after acquiring an additional 3,043 shares during the period. Bank of Montreal Can increased its stake in shares of Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after acquiring an additional 3,069 shares during the period. Finally, Mizuho Securities Co. Ltd. acquired a new stake in shares of Intellia Therapeutics in the second quarter worth $64,000. Hedge funds and other institutional investors own 81.63% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Story: What are defining characteristics of a correction?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.